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Abstract
Background Bronchoscopic procedures are common in the
clinical setting, with estimates indicating 500,000 are
undertaken per year in the USA alone. These procedures
are generally regarded as safe. Unfortunately, a risk of
cross-contamination between patients, with possible sub-
sequent infection, is associated with the re-usable tech-
nology typically used in these procedures.
Objective Our objective was to conduct an early cost-ef-
fectiveness analysis (CEA) of single-use flexible video
bronchoscope technology compared with the current reu-
sable technology in a US hospital intensive care setting.
Methods We conducted a CEA to determine an incre-
mental cost-effectiveness ratio (ICER), and constructed a
decision analytic model based on the best available evi-
dence from a literature search and a Delphi panel. We also
conducted several one- and two-way sensitivity analyses
and a probabilistic sensitivity analysis to illuminate the
uncertainty associated with the estimates.
Results The literature search showed ample evidence of
risk, albeit little of it was quantifiable. Estimates from the
Delphi method found approximately a 3% risk of cross-
contamination and approximately a 21% risk of subsequent
infection. Pneumonia was estimated as the most likely
manifestation of infection. The CEA showed a saving of
$US118 per procedure and elimination of 0.7% of the risk
of infection with the single-use technology. Relevant sen-
sitivity analyses generally validated this result.
Conclusion This study suggests that implementation of the
single-use technology in the intensive care unit is cost
effective in most scenarios. However, this result should be
interpreted with caution because of the lack of certain
knowledge on this particular topic.
Key Points for Decision Makers
Risks of cross-contamination and post-endoscopic
infection from bronchoscopic procedures is under-
researched.
A single-use flexible video bronchoscope would
eliminate any given risk of cross-contamination.
Early assessment of the cost effectiveness of single-
use bronchoscopes indicates potential hospital
savings and patient benefits from infections avoided.
1 Introduction
Although definitive assessment of cost effectiveness may
require long-term evidence from randomized trials, it is
important to begin to estimate likely cost effectiveness
early in the life cycle of new technologies [1]. Such esti-
mates can help prioritize internal development plans,
indicate which parameters need further research and inform
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early adopters of the technology [1–3]. Single-use flexible
video bronchoscopes is one such new technology in an area
with limited evidence.
Bronchoscopes give healthcare professionals both visu-
alization of and access to the affected tissue to investigate
symptoms, confirm diagnoses or treat a patient. For
instance, the instrument allows for visual orientation into
an individual lobe or segment bronchi or allows for bron-
choalveolar lavage. Estimates indicate 500,000 broncho-
scopic procedures take place per year in the USA alone [4].
Bronchoscopic procedures are common in clinical settings
because they are generally recognized as safe [5]. Com-
plications associated with flexible bronchoscopy are usu-
ally minor and relate to procedure or sedation [5]. Common
complications include bleeding, pneumothorax and infec-
tion; however, other risks, such as sore throat, heart attack
and fever, also exist [6–8].
A single-use flexible video bronchoscope would elimi-
nate any given risk of cross-contamination. The decision as
to whether or not a hospital should buy and implement the
new and possibly better technology requires economical,
ethical and clinical considerations. This study provides a
health economic perspective on the issue by conducting a
cost-effectiveness analysis (CEA) of single-use flexible
video bronchoscopes and comparing this with reusable
flexible video bronchoscopes when applied in a typical
intensive care unit (ICU). ICUs are characterized by patients
with generally low immune responses, and they often rely on
mechanical ventilation, bypassing normal immune respon-
ses in the upper airways. This patient group is therefore
particularly prone to infection. However, the risk of cross-
contamination and infection is not well investigated. Given
the limited clinical evidence, this study should be interpreted
as an early assessment of the likely cost effectiveness of
single-use flexible video bronchoscopes.
1.1 Reprocessing of Reusable Flexible
Bronchoscopes
When a procedure is completed, the standard reusable flex-
ible bronchoscope needs to be reprocessed prior to reuse. All
parts of the reusable technology are reused. Flexible bron-
choscopes initially receive manual cleaning (removing
organic debris and microorganisms) at the site before being
moved to a designated reprocessing work area for leak
testing and possible automated cleaning. Depending on the
device material, it undergoes either disinfection (the elimi-
nation of all microorganisms other than a small number of
bacterial spores) or sterilization (the complete destruction of
all forms ofmicrobiological life) [9].When this reprocessing
has been performed according to the approved labelling from
themanufacturer, the flexible bronchoscopes are stored in an
appropriate storage cabinet. Each flexible bronchoscope
requires a specific reprocessing regime. This results in a
range of different instructions on product labels, such as the
varying use of detergents [10]. Some healthcare facilities
also use automated endoscope reprocessors (AERs) to
implement a mechanical disinfection method. Since the
bronchoscopes are in contact with mucous membranes and
have a moderate degree of infection risk if contaminated at
the time of use, they are categorized as semi-critical devices
[11] and should therefore optimally be sterilized. However,
the device materials do not always permit this reprocessing
method. If the reusable bronchoscope is heat-labile, low-
temperature reprocessing should be applied, such as high-
level disinfection (HLD) [10]. HLD procedures vary [9] but
commonly involve the elimination of certain microorgan-
isms to an acceptable extent. The US FDA maintains an
updated list of approved sterilants and high-level disinfec-
tants for this purpose [12].
1.2 Risks of Cross-Contamination and Post-
Endoscopic Infection
The risk of adverse events due to inappropriate cleaning,
disinfection or rinsing, or lack of leak testing and drying as
a cause of cross-contamination is well described in the
literature [13–15]. Some of these failures are associated
with human error and some suggest additional or improved
training as part of the solution [16]. Yet some of these
cases involving inadequate cleaning might be due to dif-
ficult conditions for personnel [17].
Biofilm formation is of special concern in reprocessing
[18, 19]. A biofilm can be defined as a microbially derived
sessile community characterized by cells that are irre-
versibly attached to a substratum, interface or each other
and that are embedded in a matrix of extracellular poly-
meric substances that produce and exhibit an altered phe-
notype with respect to growth rate and gene transcription
[20]. The structure and physiological attributes of biofilms
make microorganisms in biofilms, in contrast to a normal
planktonic state, very resistant to antimicrobial agents,
whether antibiotics, disinfectants or germicides [20].
Outbreaks of post-endoscopic infection and cross-con-
tamination related to biofilm development inside endo-
scope channels and AERs have been reported in the
literature [15, 21]. Biofilms can be removed from artificial
surfaces by physical methods, e.g. thorough brushing of
bronchoscope channels combined with chemical treatment
[9]. Unfortunately, because of the composition and nature
of the flexible bronchoscope construction, it is difficult to
consistently brush and clean properly [21–23]. This is
particularly so when the bronchoscope is damaged [19, 24].
It is difficult to know whether the flexible bronchoscope is
damaged [18, 21, 22, 24], and therefore a potential risk
exists for bacterial colonization of cracks, grooves and pits.
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The resistance of microorganisms in biofilms to decon-
tamination is an issue of concern not only for the bron-
choscopes but also for the AERs. If a contaminated
reusable bronchoscope is introduced to an AER, it could
allow the formation of biofilm in the AER itself. This AER
could then contaminate the next, originally sterile, reusable
bronchoscope being reprocessed, thereby acting as a source
of contamination [25]. In addition, bacterial spores are not
necessarily eliminated by exposure to disinfectants [9]. A
few disinfectants, termed chemical sterilants, are able to
kill bacterial spores after prolonged exposure (3–12 h) [9].
Although much effort is being put into reprocessing
reusable bronchoscopes, reports are continually being
published showing problems with cross-contamination
despite strict adherence to reprocessing labelling instruc-
tions [15, 18]. Complications during these procedures are a
reality in which clinicians work and to which patients are
compelled to submit. Nonetheless, the risk of cross-con-
tamination of a pathogen from one patient to another as a
result of inadequate bronchoscope reprocessing might be
preventable. However, research in this context is still
sparse, and no direct quantified risk has been identified in
the literature. In 2015 alone, the FDA published new
guidelines for reprocessing, issued safety communications
on bronchoscopes and AERs, required manufacturers to
conduct post-marketing surveillance studies and sent
warning letters to at least three major manufactures
[26–28]. It is in the interests of patients, clinicians and
suppliers in this industry to further investigate the reality.
Until then, we are dealing with uncertainty.
In an effort to minimize this risk of cross-contamination,
a range of alternative pathways could be taken, such as the
use of single-use protective sheets, thorough and repetitive
education of healthcare personnel or further development
of reusable bronchoscope materials and AERs [29]. Still,
these methods of dealing with risk will only minimize, not
eliminate, the uncertainty.
2 Methods
2.1 Health Economic Evaluation
We constructed a decision analytic model on the basis of
the best available evidence to estimate the short-term costs
and benefits of single-use flexible video bronchoscopes
compared with reusable flexible video bronchoscopes
[30, 31] (Fig. 1). The setting was a US hospital ICU. The
time horizon was short term (within 1 year). Costs were
estimated in $US, year 2015–2016 values. The model was
drawn up in TreeAgePro 2014 with the Healthcare Module
addition.
2.2 Risk
To inform the model with data on the effect, we conducted
a literature search using a mix of methods, primarily a
PICO (population, intervention, comparator, outcome)
search of PubMed, the Cochrane Library, and Embase
using the medical subject heading (MeSH) terms ‘bron-
choscopy’, ‘risk’, ‘cross-contamination’, ‘reusable’, ‘sin-
gle-use’, ‘disposable’, ‘infection’, ‘prevention’ and
‘reprocessing’ (period: 1980–2015). Typical manifestations
of infection in this context are also worthy of attention in
this process. Only studies from Europe, the USA and
Canada were included. We screened and evaluated the
Fig. 1 Decision analytic model for cost effectiveness of single-use flexible video bronchoscopes
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articles and extracted the relevant data. Many reports in the
literature indicate a non-quantifiable risk of cross-contam-
ination and subsequent infection due to bronchoscopy
[15, 32, 33]. A broad consensus exists that a risk is indeed
generally present and that cases are under-reported
[5, 6, 15, 17, 24, 34, 35]. To inform the decision model
with sufficient data, we needed to find or estimate the risk
of cross-contamination and infection. Both the effect of
using reusable flexible video bronchoscopes and the effect
of using single-use flexible video bronchoscope were
needed for quantitative analysis. We therefore obtained
expert consensus using the Delphi method to structure the
communication and deliver the circumstances described in
detail below. The literature findings support or validate the
estimation of the risk of cross-contamination and infection
for the estimates provided from a panel of experts. The
uncertainties associated with the estimates of the effects
given by the Delphi panel are also reflected in the applied
probability distributions.
We used the findings from the literature review to
identify international experts and researchers from differ-
ent continents who were relevant for inclusion in the
Delphi panel. The Delphi method is a method of structured
communication allowing a group of individuals to deal
with a complex problem [36, 37]. We used the sub-version
‘conventional Delphi’ [36, 37]. First, a questionnaire was
sent to the identified group. Questionnaires were completed
and returned, and we summarized the results. A new
questionnaire (see the Electronic Supplementary Material
[ESM]) based on the results of the first round was then sent
back to the respondent group (for further details see the
ESM). This allowed the respondents to re-evaluate their
original answers. This technique combines polling and
conference procedures in a way that facilitates unrestricted
professional estimation [38]. The level of expertise was
rated by the authors on the basis of either the frequency of
appearance in the literature, the frequency of citation or via
conversation with the expert in question. Of 14 contacts,
eight completed the process. All eight experts completed
both questionnaires. Expert identities were anonymised;
however, all were experienced clinicians and researchers
within the field and together they represented both Europe
and North America. We calculated the standard error of the
sample mean based on the results from this method, and
used this as input in the approximation of the relevant
statistical distribution for probabilistic sensitivity analysis
(PSA).
2.3 Cost
The cost per procedure using a reusable flexible video
bronchoscope was estimated based on literature findings
[39–43] at $US221, year 2015 values. This is the mean cost
per use over the lifespan of the reusable technology.
Given existing variance in the literature estimates, spe-
cial attention was paid to this parameter in the two-way
sensitivity analysis. We based our calculations for single-
use flexible video bronchoscopes on the Ambu aScopeTM
3. The cost of using a single-use flexible video broncho-
scope (Ambu aScopeTM 3) per procedure, including the
monitor (Ambu aViewTM), was estimated at $US305.
This estimate is based on the price of one single-use flex-
ible video bronchoscope (for US hospitals, the purchase
price would be approximately $US300) and the recom-
mended number of monitors needed based on the average
number of procedures from the identified cost analyses in
the literature. As these recommendations are based on
estimates, and this technology is likely to increase waste
handling, some uncertainty is connected with this param-
eter. We are dealing with a group of patients who already
have various conditions (those for which they were
admitted to the ICU setting), and so a cross-contaminated
and subsequently infected patient would have additional
pneumonia, not pneumonia alone. We were therefore
interested in finding the marginal cost in a setting similar to
our case setting. We considered ventilator-associated
pneumonia (VAP), assuming it would be the clinically
most appropriate substitute for our infection manifestation,
as it also constitutes a problem supplementary to the
original condition for which the patient was admitted. The
cost per VAP case was found in the literature in a sys-
tematic review of US clinical settings [44] that identified
the average marginal cost of typical infections. The aver-
age marginal cost of VAP was identified as $US28,383 per
case.
2.4 Sensitivity Analyses
We conducted several analyses to test the robustness of the
base-case results and to provide adequate insight for the
decision maker, applying both deterministic sensitivity
analyses and PSA. We conducted one-way (univariate)
sensitivity analysis for all parameters in the model to explore
the impact on the incremental cost-effectiveness ratio
(ICER) of changing the value of the parameter while keeping
all other parameter values unchanged and conducted two-
way sensitivity analyses for different price levels for the new
technology. PSA was performed to estimate the decision
uncertainty by using the specified distributions in a second-
order Monte Carlo simulation with 1000 samples of mean
ICER. Results from the PSA are presented in an ICER
scatterplot to illustrate the likelihood of savings and associ-
ated reduction in risk of an adverse event (such as nosoco-
mial infection with pneumonia).
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3 Results
Results from the Delphi exercise showed reasonably sim-
ilar values during both rounds of questionnaires. When
asked to estimate the typical condition an infected patient
in this context would have, all answered ‘‘pneumonia’’ in
both rounds. See Table 1 for the final results from the
Delphi exercise as well as the other parameter values used.
The CEA base-case results indicate that the single-use
flexible video bronchoscope technology is the preferred
technology, as this option is less costly and more effective
in regard to cross-contamination and subsequent infection.
Using the current technology is estimated to have an
average cost of $US424 and to hold a 0.7% risk of infec-
tion. The newer technology has an average cost per use of
$US305 and a 0% risk of infection. Results show a possible
saving of $US118.56 per procedure and the elimination of
a 0.7% risk of infection if the single-use option is adopted
instead of the current technology. Table 2 presents an
overview of the different one-way sensitivity analyses
performed.
Figure 2 uses two-way sensitivity analysis graphs to
illustrate that the higher the internal cost of reprocessing,
quality assurance and repairs associated with the reusable
Table 1 All parameter values used in the model and their respective standard errors, distributions and sources
Parameter Base-case value (SE) Distribution Source
Effects
Reusable flexible video bronchoscope risk of cross-contamination 3.375% (0.4199) Beta Delphi panel
Reusable flexible video bronchoscope risk of subsequent infection 21.25% (2.7951) Beta Delphi panel
Single-use flexible video bronchoscope risk of cross-contamination 0% (0) NA NA
Single-use flexible video bronchoscope risk of subsequent infection 0% (0) NA NA
Costs
Reusable flexible video bronchoscope cost per procedure $US221 (44) Gamma [35–39]
Single-use flexible video bronchoscope cost per procedure $US305 (15) Gamma Producer (Ambu A/S)
Cost per case of VAP $US28.383 (4257) Gamma [40]
NA not available, SE standard error, VAP ventilator-associated pneumonia
Table 2 Base-case result and one-way sensitivity analyses
Scenario D cost ($) D effect (avoided
risk of infection)
ICER (cost per
avoided infection)
Base-case (see Table 1) –119 0.0072 –16,554
Below various one-way sensitivity analyses
When cost of use of the reusable technology is $100 0.68 0.0072 68
When cost of use of the reusable technology is $200 –99 0.0072 –13,795
When cost of use of the reusable technology is $300 –199 0.0072 –27,684
When cost of use of the reusable technology is $400 –299 0.0072 –41,573
When cost of use of the reusable technology is $500 –399.32 0.0072 –55,462
When cross-contamination for reusable technology is set to 0% 220 1.0000 220
When cross-contamination for reusable technology is set to 2.5% –65 0.0053 –12,296
When cross-contamination for reusable technology is set to 5% –216 0.0106 –20,340
When cross-contamination for reusable technology is set to 7.5% –366.03 0.0159 –23,021
When cross-contamination for reusable technology is set to 10% –516 0.0212 –24,361
When infection rate for reusable technology is set to 10% –11 0.0034 –3307
When infection rate for reusable technology is set to 15% –59 0.0051 –11,665
When infection rate for reusable technology is set to 20% –107.74 0.0068 –15,845
When infection rate for reusable technology is set to 25% –156 0.0085 –18,352
When infection rate for reusable technology is set to 30% –204 0.0102 –20,024
When infection rate for reusable technology is set to 35% –252 0.0119 –21,218
When infection rate for reusable technology is set to 40% –300.75 0.0136 –22,114
ICER incremental cost-effectiveness ratio
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technology, the more advantageous it is to use the single-
use technology (as indicated in red).
A scatterplot from the PSA is illustrated in Fig. 3. The
majority of calculated ICERs are in the south-eastern
quadrant, indicating a likelihood of net savings for the
hospital of over 97%. A 95% confidence ellipse has been
applied to the scatterplot.
4 Discussion
This is the first study to utilize a CEA with the aim of
indicating whether implementation of a single-use flexible
video bronchoscope (Ambu aScopeTM 3) is cost effective
when solely looking at cross-contamination and possible
subsequent infections with bronchoscopes in a typical ICU
Fig. 2 Two-way sensitivity analyses. Red area indicates net savings
from single-use technology compared with reusable bronchoscopes.
Blue area indicates that re-usable technology is cheaper. Potential
health benefits from avoided infections are not included in the two-
way sensitivity analyses
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setting compared with current best practice involving reu-
sable flexible video bronchoscopes.
Based on limited evidence, the model suggests that
implementation of the single-use technology in the ICU is
cost saving and associated with increased patient safety.
PSA and other sensitivity analyses generally confirmed
this. However, the results should be interpreted with cau-
tion because definite knowledge is lacking on this partic-
ular topic.
Despite this lack, it can be argued that it is still neces-
sary to undertake health economic evaluations very early in
the adoption process for new health technologies to direct
attention to possible improvements [3]. In constructing the
decision model, the decision makers have an opportunity to
see a simplified model of the real world. The results pro-
vide an intuitive and visual approach to the decision at
hand. The gaps in the evidence have been highlighted in
the literature review, and the Delphi method has been used
to accommodate this issue. As with any model, this anal-
ysis has its limitations, which in this case involve data
availability and our assumptions.
The risks of cross-contamination and post-endoscopic
infection were estimated by a panel of experts using the
Delphi method. The method is characterized by its con-
siderable uncertainty, and it was only possible to obtain the
full participation of eight of the 14 international (anony-
mous) experts we contacted. We have no reason to question
the validity of the panel estimates. The advantages of
making the expert panel anonymous is that it allows for
open answers about what is sometimes a sensitive topic.
Possible disadvantages include the lack of transparency.
Other possible limitations of this health economic evalua-
tion concern the study perspective, the model structure, the
time horizon and other complications and costs. When
thinking outside of the healthcare sector perspective, there
are likely to be more outcomes that have not been included.
An example of this would be ICU patients’ delayed
recovery due to cross-contamination and subsequent
infection, which would delay their return to the labour
market. The benefit of implementing the new safer tech-
nology is thereby underestimated from a societal perspec-
tive. To make the results as precise as possible, a clear
delineation of the study perspective was chosen, as it deals
with a very complex reality. Looking at the workflow in an
ICU setting, availability because of repairs or downtime in
relation to reprocessing could be of concern. Therefore,
implementing a single-use technology could mean the
constant availability of flexible video bronchoscopes. This
is important when dealing with one or perhaps multiple
emergency situations. This scenario was not included in the
analysis but could mean the benefits of implementing the
new single-use technology are underestimated. The lack of
availability can also result in personnel waiting time and
thereby added costs per procedure.
Environmental factors, such as increased waste disposal
and handling with disposable single-use flexible video
Fig. 3 Scatterplot from probabilistic sensitivity analyses using 1000 s-order samples
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bronchoscopes, could influence the result through an
overestimation of the benefits. Ethical considerations are
also a subject for discussion. Some would argue that patient
safety should always come first and that safer technology
should always be implemented regardless of the associated
cost. This could also mean that certain healthcare providers
might not offer certain treatments. Others would argue that
resources are scarce and prioritization should be based on
specific evaluations to secure the best safety for the money.
Finally, our study only applies to an ICU setting with
immunocompromised patients, and the probabilities of risk
have been estimated based on this setting. Therefore, the
choice of strategy might differ in case settings other than
ICUs.
Remarkably few cases of cross-contamination have been
reported in the literature, and more research, preferably
prospective, is needed to increase the level of evidence on
this topic.
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